Recent developments in oral chemotherapy options for gastric carcinoma

Drugs

Volumn 58, Issue SUPPL. 3, 1999, Pages 85-90

  Ajani, Jaffer A ^a,b   Takiuchi, Hiroya ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; MITOMYCIN; TEGAFUR; UFT; URACIL;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; DRUG COMBINATIONS; ETOPOSIDE; HUMANS; STOMACH NEOPLASMS; TEGAFUR; URACIL;

EID: 0033510507     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5-27
2. Pazdur R, Coia L, Hoskins W, et al, editors. Cancer management: a multidisciplinary approach. Medical, Surgical & Radiation Oncology (1st ed.) Huntington: PRR, 1996: 87-95
3. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and metholrexate in advanced gastric cancer. Cancer 1993; 72: 37-41
4. Pyrhonen S, Kuitunen T, Kouri M. A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Ann Oncol 1992; 3: 12A
5. Glimelius B, Hoffmann K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189-90
6. Scheithauer W, Komek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial [abstract 68]. Proceedings of the Second International Conference on Biology, Prevention, and Treatment of GI Malignancy; 1995 Jan 9-12; Koln, Germany
7. Comis RL, Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1974; 1: 285-304
8. Kelsen DP, Magill G, Cheng E, et al. Phase II trial of etoposide (VP-16) in the treatment of upper gastrointestinal malignancies. Proc Am Soc Clin Oncol 1982; 1: 96A
9. Lacave A, Izarzugaza I, Anton Aparicio LM, et al. Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 1983; 6: 35-8
10. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253: 2061-7
11. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin -a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-31
12. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epiruhicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-7
13. Wilke H, Wils J, Rougier P, et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/FU in advanced gastric cancer. Proc Am Soc Clin Oncol 1995; 14: 206A
14. Slevin ML. Low-dose oral etoposide: a new role for an old drug? [editorial] J Clin Oncol 1990; 8: 1607-9
15. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 1992; 19 Suppl. 14: 36-9
16. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer. A phase II trial. J Clin Oncol 1990; 8: 1613-7
17. Carney DN, Grogan L, Smit EF, et al. Single-agent oral etoposide for elderly small cell lung cancer patients. Semin Oncol 1992; 17 Suppl. 2: 49-53
18. Unemi N, Takeda S, Tajima K, et al. Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil. I. Effect of co-administration of uracil on the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and the level of 5-fluorouracil in AH-130 bearing rats. Chemotherapy 1981; 29: 164-75
19. Unemi N, Takeda S, Tajima K, et al. Studies on combination therapy with 1-(tetrahydro-2-furanyl)-5-fluorouracil plus uracil. II. Chemotherapy 1981; 29: 176-84
20. Pazdur R, Covington WP, Brown NS, et al. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil. Proc Am Soc Clin Oncol 1996; 15: 474A
21. Namatame K, Sasaki E, Ko Y, et al. A double-blind comparison of Fura plasma concentration by oral (UFT) vs continuous intravenous infusion (5-FU) [in Japanese]. Jap J Cancer Chemother 1993; 20: 2417-9
22. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333-8
23. Murakami M, Ota K. Clinical results of UFT therapy for malignant tumors under cooperative study. Jap J Cancer Chemother 1980; 7: 1579-86
24. Watanabe H, Yamamoto S, Naito T. Clinical results of oral UFT therapy under cooperative study. Jap J Cancer Chemother 1980; 7: 1588-96
25. Nakano Y, Taguchi T, Sakai K, et al. Clinical phase II study of UFT by cooperative study group. Jap J Cancer Chemother 1980; 7: 1569-78
26. Takino T, Misawa S, Edagawa J, et al. Clinical studies on the chemotherapy of advanced cancer with UFT. Jap J Cancer Chemother 1980; 7: 1804-12
27. Shirakawa S, Uehara N, Kita K, et al. Clinical trial on the effect of UFT. Jap J Cancer Chemother 1981; 8: 101-5
28. Tamura Y, Okino M, Hongo H, et al. Phase II study of UFT by collaborative study. Jap J Cancer Chemother 1981; 8: 302-7
29. Yakeishi Y, Yoshida H, Yokota H, et al. Clinical trial of UFT against malignant tumors. Jap J Cancer Chemother 1981; 8: 414-21
30. Nakajima O, Ihara K, Isoda T, et al. Phase I and II studies on a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT). Jap J Cancer Chemother 1980; 7: 1558-68
31. Nishioka K, Nomura K, Hashimoto S, et al. Clinical effect of UFT on the advanced cancer with special reference to lung cancer. Jap J Cancer Chemother 1981; 8: 294-301
32. Fukui Y, Imabayashi N, Nishi M, et al. Clinical study on the enhancement of drug delivery into tumor tissue by using UFT. Jap J Cancer Chemother 1980; 7: 2124-9
33. Data on file. Taiho Pharmaceutical Company, Tokyo, Japan
34. Malik ST, Talbot D, Clarke PI, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990; 62: 1023-5
35. Kurihara M, Izumi T, Yoshida S, et al. A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 1991; 82: 613-20
36. Sato A, Hasegawa K, Kurihara M, et al. Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. Jap J Cancer Chemother 1995; 22: 1355-62
37. Tanaka S, Umeno T, Mitsuishi K, et al. UFT/CDDP preoperative chemotherapy for progressive gastric cancer - histological antitumor effects and thymidylate synthase inhibition rate. Jap J Cancer Chemother 1995; 22: 1947-51
38. Shirasaka T, Shimamoto Y, Ohshima H, et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-72
39. Oie S, Okabe H, Takeda S, et al. Analysis of the mechanism of increased antitumor activity of UFT after combined treatment with CDDP. Jap J Cancer Chemother 1990; 17: 1321-6
40. Sawa T, Kinoshita K, Takekawa S, et al. Effect of PMUE therapy (CDDP, MMC, UFT, etoposide) in terminal gastric cancer. Jap J Cancer Chemother 1990; 17: 2381-6
41. Hayakawa M, Morise K, Sakai T, et al. Combination chemotherapy with UFT, etoposide, CDDP, adriamycin (FEPA) in advanced gastric cancer. Jap J Cancer Chemother 1989; 16: 3393-8
42. Feliu J, Gonzalez Baron M, Zamora P, et al. Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology 1997; 54 Suppl. 1: 30-7
43. Kim YH, Shin SW, Park YT, et al. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. Oncology 1997; 11: 119-23
44. Hattori T, Inokuchi K, Taguchi T, et al. Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years. Jap J Surg 1986; 16: 175-80
45. Inokuchi K, Hattori T, Taguchi T, et al. Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years. Cancer 1984; 53: 2393-7
46. Arima S, Ohsato K, Hisatsugu T, et al. Multicentre randomised study of adjuvant chemotherapy with mitomycin C and tegafur or tegafur-uracil in gastric cancer. Eur J Surg 1994; 160: 227-32
47. Maehara Y, Watanabe A, Kakeji Y, et al. Postgastrectomy prescription of mitomycin C and UFT for patients with stage IV gastric carcinoma. Am J Surg 1990; 160: 242-4
48. Ohtsu A, Sakata M, Taguchi T, et al. A phase II study of S-1 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998; 17: 262A